Pioneering Alternative Treatments for NLPHL: My Journey into Lymphoma Research

When I was diagnosed with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma (NLPHL), I began a journey to understand not only the disease but the ways we treat it. Unlike many other cancers, NLPHL lacks research on specific, low-toxicity treatments, often defaulting to broader lymphoma protocols that can be harsh. This realization drove me to explore alternative therapies with the goal of reserving chemotherapy as a last resort.

My current focus is on using HDL nanostructures to control cholesterol delivery directly to NLPHL cells. HDL, or high-density lipoprotein, could potentially target lymphoma cells with high specificity, reducing toxicity to healthy cells. I’m delving into the mechanisms of this approach, laying the groundwork for future lab testing that could someday bring a tailored, less toxic treatment to NLPHL patients. This research feels deeply personal, and my goal is to contribute to a kinder, more effective therapeutic pathway for others facing this rare lymphoma.